Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GOP, Dem Lawmakers Differ on Strategies To Repeal Device Tax

This article was originally published in The Gray Sheet

Executive Summary

While Republican Congressman Pitts says he wants to inject language to repeal the 2.3 percent excise tax as part of a GOP ObamaCare “Off-Ramp” bill expected this summer, Democratic Senator Klobuchar says she is working on finding a pay for by the end of the year that would appease her Democratic colleagues and the White House.

You may also be interested in...



10 Senate Dems Line Up On Paper Behind Device Tax Repeal

There are at least 10 Democrats in the Senate who have either introduced device tax repeal bills in the most recent legislative session or signed on as cosponsors to a repeal bill. Those lawmakers could join all Republicans in the Senate to pass permanent repeal, but a busy Senate agenda and fiscal concerns could stand in the way.

Ultimate Burden Of Device Tax – After Deductions – Debated At Senate Hearing

Sen. Debbie Stabenow, D-Mich., said the harsh impact of the device tax on industry after deductions are accounted for is less than a B. Braun official at an April 23 Senate Finance Health Care Subcommittee claims.

Industry Groups Tag-Team To Attack Device Tax

AdvaMed and MDMA simultaneously released survey results from their member companies arguing the tax has hurt jobs and investment in the industry and will continue to do so if it is not repealed.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033855

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel